Apellis Pharmaceuticals Company Insiders

Apellis Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.0513 % which means that it generated a profit of $0.0513 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.141 %, meaning that it created $0.141 on every $100 dollars invested by stockholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2026. Return On Capital Employed is likely to drop to -0.22 in 2026. At this time, Apellis Pharmaceuticals' Fixed Asset Turnover is comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.83 in 2026, whereas Return On Tangible Assets are likely to drop (0.21) in 2026. Common Stock Shares Outstanding is likely to gain to about 149.6 M in 2026, despite the fact that Net Loss is likely to grow to (557.6 M). The majority of Apellis Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Apellis Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Apellis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Apellis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Some institutional investors establish a significant position in stocks such as Apellis Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Apellis Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Apellis Pharmaceuticals Workforce Comparison

Apellis Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of 0.04 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.49 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.49.

Apellis Pharmaceuticals Insider Trading History

Apellis Pharmaceuticals Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Apellis Pharmaceuticals often depends on how effective the management is. Apellis Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Apellis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Apellis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Apellis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apellis Pharmaceuticals. Check Apellis Pharmaceuticals' Beneish M Score to see the likelihood of Apellis Pharmaceuticals' management manipulating its earnings.

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.